IFNB1 and myeloid sarcoma: As of today, over a dozen DMTs are approved for the treatment of MS, whereas before 2010, only a narrow range of therapeutic options were available: interferons beta, glatiramer acetate, and mitoxantrone, along with off-label medications such as cyclophosphamide.